TCP
IOVA icon

Tourbillon Capital Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Tourbillon Capital Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-759,400
Closed -$6.96M – 113
2015
Q2 		$6.96M Buy
+759,400
New +$8.48M 0.15% 88

Other funds holding IOVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Tourbillon Capital Partners's IOVA Position: Q3 2015 in Review

Tourbillon Capital Partners sold out of Iovance Biotherapeutics (IOVA) in Q3 2015, closing a stake of 759,400 shares — an estimated $6.96M sold.

Tourbillon Capital Partners first reported a position in IOVA in Q2 2015 and held it in 1 quarter. The position peaked at $6.96M in Q2 2015. 80 funds tracked by Wall St. Rank hold IOVA as of Q3 2015.

  • Tourbillon Capital Partners reported no remaining Iovance Biotherapeutics position as of Q3 2015 after selling out during the quarter.
  • Tourbillon Capital Partners sold 759,400 Iovance Biotherapeutics shares in Q3 2015, an estimated $6.96M.
  • Tourbillon Capital Partners first reported a position in Iovance Biotherapeutics in Q2 2015 and held it in 1 quarter.
  • Tourbillon Capital Partners's Iovance Biotherapeutics position peaked at $6.96M in Q2 2015.
  • 80 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2015.

Based on Tourbillon Capital Partners's 13F filing for Q3 2015, filed 16 Nov 2015.